{"id":1017364,"date":"2026-11-05T05:35:10","date_gmt":"2026-11-05T10:35:10","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-reports-third-quarter-2026-business-and-financial-update\/"},"modified":"2026-11-05T05:35:10","modified_gmt":"2026-11-05T10:35:10","slug":"innate-pharma-reports-third-quarter-2026-business-and-financial-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-reports-third-quarter-2026-business-and-financial-update\/","title":{"rendered":"Innate Pharma Reports Third Quarter 2026 Business and Financial Update"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwblockalignl { margin-left: 0px; margin-right: auto }\n.bwcellpmargin { margin-bottom: 0px; margin-top: 0px }\n.bwleftsingle { border-left: solid black 1pt }\n.bwlistdisc { list-style-type: disc }\n.bwpadl0 { padding-left: 0px }\n.bwrightsingle { border-right: solid black 1pt }\n.bwsinglebottom { border-bottom: solid black 1pt }\n.bwtablemarginb { margin-bottom: 10px }\n.bwtopsingle { border-top: solid black 1pt }\n.bwuline { text-decoration: underline }\n.bwvertalignt { vertical-align: top }\n.bwwidth100 { width: 100% }\n.bwwidth20 { width: 20% }\n.bwwidth80 { width: 80% }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Innate Pharma Reports Third Quarter 2026 Business and Financial Update<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li><b><i>Phase 1 dose-escalation data for Nectin-4 ADC IPH4502 to be presented at ENA 2026 on November 18, followed by a webcast and in-person event<\/i><\/b><\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li><b><i>Lacutamab, partnered with Sobi, progressing toward first patient dosing in the Phase 3 TELLOMAK-3 trial in Q1 2027, with an FDA accelerated approval filing planned in S\u00e9zary syndrome in H2 2027<\/i><\/b><\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li><b><i>AstraZeneca-led PACIFIC-9 Phase 3 trial of durvalumab in combination with monalizumab or oleclumab in unresectable Stage III NSCLC, readout expected in the first half of 2027<\/i><\/b><\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li><b><i>Cash position of \u20ac96.8 million<sup>1<\/sup> as of September 30, 2026; anticipated cash horizon until the end of Q1 2028<\/i><\/b><\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li><b><i>Conference call to be held today at 2:00 p.m. CET \/ 8:00 a.m. ET<\/i><\/b><\/li>\n<\/ul>\n<p>MARSEILLE, France&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nRegulatory News:<\/p>\n<p>\nInnate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\u201cInnate\u201d or the \u201cCompany\u201d) today reported its financial update for the nine months ended September 30, 2026.<\/p>\n<p><i>\u201cAs we approach year-end, our strengthened cash position enables us to work towards executing the next steps in advancing our strategic priorities,\u201d <b>said Jonathan Dickinson, Chief Executive Officer of Innate Pharma<\/b>. \u201cWe look forward to presenting Phase 1 dose-escalation data from IPH4502, our differentiated Nectin-4 ADC, on November 18, while actively preparing for first patient dosing in the Phase 3 TELLOMAK-3 study of lacutamab in Q1 2027. We also look forward to the readout of the AstraZeneca-led PACIFIC-9 Phase 3 trial, which includes monalizumab and is now expected in the first half of 2027.\u201d<\/i><\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\">\n<tr>\n<td class=\"bwpadl0 bwwidth100\" rowspan=\"1\" colspan=\"1\">________________<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwwidth100\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><sup>1<\/sup> Including short term investments (\u20ac20.6m) and non-current financial instruments (\u20ac6.0m).<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\">\n<tr>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth100\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwalignc bwcellpmargin\"><b>Webcast and conference call will be held today at 2:00pm CET (8:00am ET)<\/b><\/p>\n<p class=\"bwalignc bwcellpmargin\">\nAccess to live webcast:<\/p>\n<p class=\"bwalignc bwcellpmargin\"><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fevents.q4inc.com%2Fattendee%2F754351455&amp;esheet=54635399&amp;newsitemid=20261104506906&amp;lan=en-US&amp;anchor=Click+here&amp;index=1&amp;md5=9dd5537671b137a62e1cfe29fa818c25\">Click here<\/a><\/p>\n<p class=\"bwalignc bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwalignc bwcellpmargin\">\nParticipants may also join via telephone using the registration link below:<\/p>\n<p class=\"bwalignc bwcellpmargin\"><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fevents.q4inc.com%2Fanalyst%2F754351455%3Fpwd%3DyoYvfGw3&amp;esheet=54635399&amp;newsitemid=20261104506906&amp;lan=en-US&amp;anchor=Click+here&amp;index=2&amp;md5=2443030be769c32695db8b44b1bbb59f\">Click here<\/a><\/p>\n<p class=\"bwalignc bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwalignc bwcellpmargin\">\nThis information can also be found on the Investors section of the Innate Pharma website, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Finnatepharma2021ir.q4web.com%2FEnglish%2Finvestors%2Foverview%2Fdefault.aspx&amp;esheet=54635399&amp;newsitemid=20261104506906&amp;lan=en-US&amp;anchor=www.innate-pharma.com&amp;index=3&amp;md5=b07af8ddba2f0e0fe89c6523fbe4529c\">www.innate-pharma.com<\/a>.<\/p>\n<p class=\"bwalignc bwcellpmargin\">\nA replay of the webcast will be available on the Company website for 90 days following the event.<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p><b>Pipeline highlights<\/b><\/p>\n<p><b><span class=\"bwuline\">IPH4502 (Nectin-4 exatecan ADC):<\/span><\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nIPH4502 is Innate Pharma\u2019s proprietary Nectin-4-targeting ADC, combining a differentiated antibody, a proprietary stable linker and an exatecan payload, with the potential to overcome Enfortumab Vedotin (EV) resistance in urothelial carcinoma (UC) and target tumors with low or heterogeneous Nectin-4 expression beyond UC. IPH4502 is currently being evaluated in a Phase 1 trial in advanced solid tumors known to express Nectin-4 (IPH4502-101; NCT06781983).<\/p>\n<\/li>\n<li>\nAs announced in July 2026 (<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.innate-pharma.com%2Fmedia%2Fall-press-releases%2Finnate-pharma-announces-completion-enrollment-phase-1-dose-escalation-study-iph4502-novel-nectin-4-exatecan-antibody-drug-conjugate-adc&amp;esheet=54635399&amp;newsitemid=20261104506906&amp;lan=en-US&amp;anchor=Link+PR&amp;index=4&amp;md5=789523d0072c418d29f6df3c61b621f3\">Link PR<\/a>), enrollment in the Phase 1 dose-escalation of the IPH4502-101 study is complete, with 76 patients enrolled across multiple solid tumor types.<\/p>\n<\/li>\n<li>\nPhase 1 dose-escalation data will be presented as a poster at the 38th EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics, on November 18, 2026 (Barcelona).<\/p>\n<\/li>\n<li>\nFollowing the ENA presentation, Innate Pharma will host a hybrid event focused on IPH4502 on November 18, 2026, at 4:00 pm GMT (11:00 am ET) with in-person attendance in London at the IET London, Savoy Place and a live webcast accessible <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Flifescievents.com%2Fevent%2Finz37gy%2F&amp;esheet=54635399&amp;newsitemid=20261104506906&amp;lan=en-US&amp;anchor=here&amp;index=5&amp;md5=fc8d498b86d85f533dd441cad1b49bad\">here<\/a>.<\/p>\n<\/li>\n<\/ul>\n<p><b><span class=\"bwuline\">Lacutamab (anti-KIR3DL2 antibody), developed in collaboration with Sobi:<\/span><\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nAs announced on August 10, 2026 (<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.innate-pharma.com%2Fmedia%2Fall-press-releases%2Finnate-pharma-enters-strategic-partnership-sobi-license-lacutamab-t-cell-lymphoma%3Fx_dt%3D260810%26x_ed%3Dfib%26x_sec%3Ddel%26x_tier%3Dp&amp;esheet=54635399&amp;newsitemid=20261104506906&amp;lan=en-US&amp;anchor=Link+PR&amp;index=6&amp;md5=26ff4c0fa60d6557358203b6e584f80d\">Link PR<\/a>), Innate Pharma entered a strategic partnership with Sobi to license lacutamab in T-cell lymphoma.<\/p>\n<\/li>\n<li>\nFollowing closing of the transaction, Innate is advancing TELLOMAK-3, the confirmatory Phase 3 study of lacutamab in Cutaneous T Cell Lymphoma (CTCL), with first patient dosing expected in Q1 2027.<\/p>\n<\/li>\n<li>\nPhase 3 TELLOMAK-3 includes a confirmatory cohort in S\u00e9zary syndrome and a registrational cohort in Mycosis Fungoides.<\/p>\n<\/li>\n<li>\nInnate plans an FDA filing in H2 2027 for accelerated approval in S\u00e9zary syndrome based on the existing Phase 2 TELLOMAK data once the confirmatory Phase 3 study is underway (<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.innate-pharma.com%2Fmedia%2Fall-press-releases%2Finnate-pharma-announces-fda-clearance-proceed-tellomak-3-confirmatory-phase-3-trial-lacutamab-ctcl&amp;esheet=54635399&amp;newsitemid=20261104506906&amp;lan=en-US&amp;anchor=Link+PR&amp;index=7&amp;md5=161b46326005d70d43232b26276985d1\">Link PR<\/a>).<\/p>\n<\/li>\n<\/ul>\n<p><b><span class=\"bwuline\">Monalizumab (anti-NKG2A antibody), developed in collaboration with AstraZeneca:<\/span><\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nEnrollment is complete in the AstraZeneca-sponsored Phase 3 PACIFIC-9 study evaluating durvalumab in combination with monalizumab or oleclumab in patients with unresectable Stage III NSCLC who have not progressed following platinum-based chemoradiation therapy.<\/p>\n<\/li>\n<li>\nAs announced on October 27 (<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.innate-pharma.com%2Fmedia%2Fall-press-releases%2Finnate-pharma-pacific-9-phase-3-trial-readout-timing-updated-h1-2027&amp;esheet=54635399&amp;newsitemid=20261104506906&amp;lan=en-US&amp;anchor=Link+PR&amp;index=8&amp;md5=4cc034cdef1c7b950214e48bc636c9ad\">Link PR<\/a>), AstraZeneca has updated the expected timing for the PACIFIC-9 Phase 3 trial high-level data readout to the first half of 2027, from the second half of 2026 previously. The revised timing reflects the event-driven nature of the study.<\/p>\n<\/li>\n<\/ul>\n<p><b>Corporate update<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nFr\u00e9d\u00e9ric Lombard, Chief Financial Officer, will step down from his position on December 31, 2026, to pursue new career opportunities. The Company thanks him for his contributions and dedication during his time with the Company. The Company has initiated a search of potential candidates to replace Mr. Lombard.<\/p>\n<\/li>\n<li>\nAs of September 30, 2026, the balance available under our April 2023 sales agreement under the At-The-Market program remains at $75 million.<\/p>\n<\/li>\n<\/ul>\n<p><b>Financial highlights for Q3 2026<\/b><\/p>\n<p>\nCash, cash equivalents and financial assets of the Company amounted to \u20ac96.8 million as of September 30, 2026, which includes the $75 million upfront payment resulting from the closing of the Sobi transaction and the aggregate gross proceeds from the \u20ac30 million private placement offering of ordinary shares that occurred in August 2026. Also as of September 30, 2026, financial liabilities amounted to \u20ac16.2 million.<\/p>\n<p>\nRevenues for the first nine months of 2026 amounted to \u20ac3.4 million (\u20ac2.3 million for the same period in 2025). Revenue from collaboration and licensing agreements mainly results from the partial or entire recognition of the proceeds received pursuant to the co-development and license agreements with AstraZeneca and research collaboration and license agreements with Sanofi.<\/p>\n<p><b>About Innate Pharma<\/b><\/p>\n<p>\nInnate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise in antibody engineering and innovative target identification, Innate Pharma is developing innovative and differentiated next-generation antibody therapeutics.<\/p>\n<p>\nInnate Pharma is advancing a portfolio of differentiated potential first- and\/or best-in-class assets, focused on areas of high unmet medical need. Its proprietary pipeline is centered on antibody-drug conjugates (ADCs), led by IPH4502, a differentiated Nectin-4 ADC in clinical development for solid tumors, and supported by a preclinical portfolio of next-generation ADC candidates. In parallel, Innate is advancing two partnered late-stage assets: lacutamab, developed with Sobi for T-cell lymphomas, and monalizumab, developed with AstraZeneca for non-small cell lung cancer (NSCLC).<\/p>\n<p>\nInnate Pharma has established collaborations with leading biopharmaceutical companies, including Sobi, Sanofi and AstraZeneca, as well as renowned academic and research institutions, to advance innovation in immuno-oncology.<\/p>\n<p>\nHeadquartered in Marseille, France, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.<\/p>\n<p>\nLearn more about Innate Pharma at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.innate-pharma.com%2F&amp;esheet=54635399&amp;newsitemid=20261104506906&amp;lan=en-US&amp;anchor=www.innate-pharma.com&amp;index=9&amp;md5=9cb6c511f9a8c32cab410cfed2454b32\">www.innate-pharma.com<\/a> and follow us on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Finnate-pharma%2F&amp;esheet=54635399&amp;newsitemid=20261104506906&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=10&amp;md5=cf1a6a0ae64ac6f8b558a55f1e85a3d4\">LinkedIn<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fx.com%2FInnatePharma&amp;esheet=54635399&amp;newsitemid=20261104506906&amp;lan=en-US&amp;anchor=X&amp;index=11&amp;md5=668429980ce570327f1b5bf671a993e7\">X<\/a>.<\/p>\n<p><b>Information about Innate Pharma shares<\/b><\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\">\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwwidth20\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><b>ISIN code<\/b><\/p>\n<p class=\"bwcellpmargin\"><b>Ticker code<\/b><\/p>\n<p class=\"bwcellpmargin\"><b>LEI<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwpadl0 bwwidth80\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nFR0010331421<\/p>\n<p class=\"bwcellpmargin\">\nEuronext: IPH Nasdaq: IPHA<\/p>\n<p class=\"bwcellpmargin\">\n9695002Y8420ZB8HJE29<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p><b>Disclaimer on forward-looking information and risk factors<\/b><\/p>\n<p>\nFor a discussion of risks and uncertainties, please refer to the Risk Factors (\u201cFacteurs de Risque&#8221;) section of the Universal Registration Document filed with the French Financial Markets Authority (\u201cAMF\u201d), which is available on the AMF website <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.amf-france.org%2F&amp;esheet=54635399&amp;newsitemid=20261104506906&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.amf-france.org&amp;index=12&amp;md5=259ad6510b2fe3b3eaf1aee656eb5a71\">http:\/\/www.amf-france.org<\/a> or on Innate Pharma\u2019s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (\u201cSEC\u201d), including the Company\u2019s Annual Report on Form 20-F for the year ended December 31, 2025, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company\u2019s website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release.<\/p>\n<p>\nThis press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261104506906r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20261104506906\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20261104506906\/en\/<\/a><\/span><\/p>\n<p>\nSt\u00e9phanie Cornen<br \/>\n<br \/>VP, Investor Relations &amp; Corporate Communications<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:stephanie.cornen@innate-pharma.fr\">stephanie.cornen@innate-pharma.fr<\/a><\/p>\n<p>\nInvestor Relations<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:investors@innate-pharma.fr\">investors@innate-pharma.fr<\/a><\/p>\n<p>\nMedia<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:communication@innate-pharma.fr\">communication@innate-pharma.fr<\/a><\/p>\n<p><b>KEYWORDS:<\/b> France Europe<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Oncology Health Clinical Trials Research Science Pharmaceutical Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20261104506906\/en\/1245155\/3\/INNATEvertnoirDS.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Innate Pharma Reports Third Quarter 2026 Business and Financial Update Phase 1 dose-escalation data for Nectin-4 ADC IPH4502 to be presented at ENA 2026 on November 18, followed by a webcast and in-person event Lacutamab, partnered with Sobi, progressing toward first patient dosing in the Phase 3 TELLOMAK-3 trial in Q1 2027, with an FDA accelerated approval filing planned in S\u00e9zary syndrome in H2 2027 AstraZeneca-led PACIFIC-9 Phase 3 trial of durvalumab in combination with monalizumab or oleclumab in unresectable Stage III NSCLC, readout expected in the first half of 2027 Cash position of \u20ac96.8 million1 as of September 30, 2026; anticipated cash horizon until the end of Q1 2028 Conference call to be held today at 2:00 p.m. CET &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-reports-third-quarter-2026-business-and-financial-update\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Innate Pharma Reports Third Quarter 2026 Business and Financial Update&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1017364","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Innate Pharma Reports Third Quarter 2026 Business and Financial Update - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-reports-third-quarter-2026-business-and-financial-update\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Innate Pharma Reports Third Quarter 2026 Business and Financial Update - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Innate Pharma Reports Third Quarter 2026 Business and Financial Update Phase 1 dose-escalation data for Nectin-4 ADC IPH4502 to be presented at ENA 2026 on November 18, followed by a webcast and in-person event Lacutamab, partnered with Sobi, progressing toward first patient dosing in the Phase 3 TELLOMAK-3 trial in Q1 2027, with an FDA accelerated approval filing planned in S\u00e9zary syndrome in H2 2027 AstraZeneca-led PACIFIC-9 Phase 3 trial of durvalumab in combination with monalizumab or oleclumab in unresectable Stage III NSCLC, readout expected in the first half of 2027 Cash position of \u20ac96.8 million1 as of September 30, 2026; anticipated cash horizon until the end of Q1 2028 Conference call to be held today at 2:00 p.m. CET &hellip; Continue reading &quot;Innate Pharma Reports Third Quarter 2026 Business and Financial Update&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-reports-third-quarter-2026-business-and-financial-update\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-05T10:35:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261104506906r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-reports-third-quarter-2026-business-and-financial-update\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-reports-third-quarter-2026-business-and-financial-update\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Innate Pharma Reports Third Quarter 2026 Business and Financial Update\",\"datePublished\":\"2026-11-05T10:35:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-reports-third-quarter-2026-business-and-financial-update\\\/\"},\"wordCount\":1262,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-reports-third-quarter-2026-business-and-financial-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261104506906r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-reports-third-quarter-2026-business-and-financial-update\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-reports-third-quarter-2026-business-and-financial-update\\\/\",\"name\":\"Innate Pharma Reports Third Quarter 2026 Business and Financial Update - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-reports-third-quarter-2026-business-and-financial-update\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-reports-third-quarter-2026-business-and-financial-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261104506906r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-11-05T10:35:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-reports-third-quarter-2026-business-and-financial-update\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-reports-third-quarter-2026-business-and-financial-update\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-reports-third-quarter-2026-business-and-financial-update\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261104506906r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261104506906r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-reports-third-quarter-2026-business-and-financial-update\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Innate Pharma Reports Third Quarter 2026 Business and Financial Update\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Innate Pharma Reports Third Quarter 2026 Business and Financial Update - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-reports-third-quarter-2026-business-and-financial-update\/","og_locale":"en_US","og_type":"article","og_title":"Innate Pharma Reports Third Quarter 2026 Business and Financial Update - Market Newsdesk","og_description":"Innate Pharma Reports Third Quarter 2026 Business and Financial Update Phase 1 dose-escalation data for Nectin-4 ADC IPH4502 to be presented at ENA 2026 on November 18, followed by a webcast and in-person event Lacutamab, partnered with Sobi, progressing toward first patient dosing in the Phase 3 TELLOMAK-3 trial in Q1 2027, with an FDA accelerated approval filing planned in S\u00e9zary syndrome in H2 2027 AstraZeneca-led PACIFIC-9 Phase 3 trial of durvalumab in combination with monalizumab or oleclumab in unresectable Stage III NSCLC, readout expected in the first half of 2027 Cash position of \u20ac96.8 million1 as of September 30, 2026; anticipated cash horizon until the end of Q1 2028 Conference call to be held today at 2:00 p.m. CET &hellip; Continue reading \"Innate Pharma Reports Third Quarter 2026 Business and Financial Update\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-reports-third-quarter-2026-business-and-financial-update\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-05T10:35:10+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261104506906r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-reports-third-quarter-2026-business-and-financial-update\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-reports-third-quarter-2026-business-and-financial-update\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Innate Pharma Reports Third Quarter 2026 Business and Financial Update","datePublished":"2026-11-05T10:35:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-reports-third-quarter-2026-business-and-financial-update\/"},"wordCount":1262,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-reports-third-quarter-2026-business-and-financial-update\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261104506906r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-reports-third-quarter-2026-business-and-financial-update\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-reports-third-quarter-2026-business-and-financial-update\/","name":"Innate Pharma Reports Third Quarter 2026 Business and Financial Update - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-reports-third-quarter-2026-business-and-financial-update\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-reports-third-quarter-2026-business-and-financial-update\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261104506906r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-11-05T10:35:10+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-reports-third-quarter-2026-business-and-financial-update\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-reports-third-quarter-2026-business-and-financial-update\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-reports-third-quarter-2026-business-and-financial-update\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261104506906r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261104506906r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-reports-third-quarter-2026-business-and-financial-update\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Innate Pharma Reports Third Quarter 2026 Business and Financial Update"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1017364","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1017364"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1017364\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1017364"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1017364"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1017364"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}